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Abstract
Background Studies on palliative care of head and neck cancer (HNC) patients are scarce although the affected patient 
population is quite large.
Objective To evaluate the role of a specialised palliative-care pathway of HNC patients.
Patients and methods Data on all HNC patients who were treated at the Helsinki University Hospital Palliative Care Center 
during 1 year were retrospectively reviewed. The analysis comprised 60 patients (49 males; mean age 67 years; range 28–88). 
All patients had a minimum follow-up of 1 year or until death.
Results Fifty-nine (98%) out of the 60 patients died during the follow-up period. Median survival after diagnosis was 11 
months (range 3 weeks–11.9 years) and after withholding disease-specific therapies 3 months (range 0–16). Thirty-three 
(55%) patients received palliative radiotherapy, 27 (45%) had PEG tube and 17 (28%) tracheostomy. Thirty-seven (66%) 
patients visited an emergency department (ED) (median 1.3 visits; range 0–6) and 21 (35%) were hospitalised at the university 
hospital during the palliative period. The most common severe complications were infection (also the most common reason 
for ED visits and hospitalisation), bleeding (four massive airway bleedings with one death), delirium and airway obstruction 
(one emergency tracheostomy). Twelve (35%) out of the 34 patients who were referred to specialised home care died at home 
as compared with three (12%) out of the 26 patients not supported by a specialised home-care team.
Conclusions Severe complications leading to an emergency unit visit and hospitalisation are common among HNC patients in 
their relatively short palliative period reflecting the need for early-integrated palliative care. Collaboration with a specialised 
palliative home-care team seems to increase end-of-life care at home.
Keywords Head and neck cancer · Palliative care · Terminal care
Introduction
Each year approximately 800 head and neck cancers (HNCs) 
are diagnosed in Finland. In 2014, 292 of them were regis-
tered in the Helsinki University Hospital area with a refer-
ral area of 1.9 M [1]. The incidence and survival rates vary 
according to primary tumour site and stage of the disease 
[2–4]. Standard treatment for early-stage HNC is either sur-
gery or radiotherapy. In locally advanced diseases, it consists 
of either definitive chemoradiotherapy, or surgical resection 
of the primary tumour and neck dissection combined with 
postoperative radiotherapy.
According to the literature, 5–14% of all patients diag-
nosed with HNC are offered palliative care without any life-
prolonging treatments at first presentation [2–5]. Usually a 
decision for palliative approach is made due to advanced, 
either inoperable or metastatic cancer, poor overall health or 
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other medical conditions that contraindicate cancer-specific 
treatments. Also, persistent or recurrent tumour growth may 
show resistance to all available treatment modalities. Overall 
survival of patients with non-curable HNC is poor, approxi-
mately less than 6 months [6, 7].
Palliative care of HNC patients with difficult symptoms, 
such as airway obstruction, dysphagia, bleeding, malodorous 
wounds and extreme cachexia, remains a challenge [8–10]. 
Patients may need a tracheostomy for compromised airway. 
Cachexia could be a paraneoplastic symptom, but also due 
to difficult or painful swallowing, and a PEG tube may be 
needed. Heavy symptom burden, changed body image and 
impaired physical functioning cause substantial psychosocial 
distress for the patients and their families [11]. Access to 
specialised palliative care is needed to ensure good quality 
of care and a dignified death. Previously published studies 
among patients with different types of cancer have found that 
early-integrated palliative care has led to improved quality 
of life and reduced costs [12–16].
Studies on palliative care of HNC patients are scarce 
despite the heavy symptom burden experienced by this 
patient population. Our aim was to describe the current 
status of palliative care of HNC patients in our university 
hospital region and to evaluate the specialised palliative care 
pathway between the Cancer Center Palliative Unit and pal-
liative care providers in primary health care.
Patients and methods
This retrospective study consists of 60 HNC patients in the 
palliative phase of their disease. The patients were treated at 
the Center of Palliative Care (Palliative Center) at the Com-
prehensive Cancer Center of the Helsinki University Hospi-
tal (HUH) during a 12-month-period between 1 May 2014 
and 30 April 2015. The follow-up period for all patients was 
12 months or until death. In this study, palliative phase is 
defined as a disease period when curative or life-prolonging 
treatment can no longer be offered. This covered the period 
from the decision to abstain from cancer-specific treatments 
(except palliative radiotherapy or surgery for symptom con-
trol) to death.
The patients were identified from hospital registries using 
the International Classification of Disease (ICD-10) coding 
for carcinoma of tongue, other sites in oral cavity, salivary 
glands, tonsils, pharynx (C01–C14), sinonasal area, and 
larynx (C30–C32). Data on patient demographics, tumour 
characteristics, and previous cancer treatments, as well as 
data on visits to the Palliative Center or emergency depart-
ment and hospitalisation periods were recorded from the 
respective hospital charts. Data on the cause and place of 
death were collected from death certifications.
An institutional research approval was granted for the 
study design. Permission to access Finnish Cancer Registry 
data was granted by the National Institute of Health and 
Welfare.
Palliative pathway
In Finland, treatment of HNC patients is centralised to the 
five university hospitals. At our university hospital district, a 
multi-disciplinary tumour board, including surgeons, medi-
cal and radiation oncologists, radiologists, pathologists, pal-
liative-care specialist, and a specialist nurse, is responsible 
for all primary treatment recommendations.
The palliative pathway of HNC patients in our hospital 
district was re-organised in March 2014. Since then, all 
patients with non-curable HNC have been systematically 
referred to the Palliative Center for specialist-level palliative 
care. Palliative Center is also responsible for coordination of 
the care according to a regional palliative-care pathway. The 
end-of-life care could be provided by a specialised hospice, 
specialised community hospital wards, general community 
hospital wards, and home care by specialised or general 
teams depending on the region. During the data collection 
time, there were specialised palliative-care services available 
mainly in larger cities in the HUH region. These included 
one hospice, two specialised wards and several specialised 
palliative home-care teams.
Results
Patient demographics and tumour characteristics are pre-
sented in Table 1. The mean age of the patients was 67 years, 
and majority of them were male. Forty-seven (77%) had 
major comorbidities of which the most common ones were 
hypertension in 25 (41%) patients, coronary heart disease in 
11 (18%), and diabetes in 10 (16%) patients.
Fourteen (25%) patients had local or locally advanced dis-
ease, 16 (26%) had locally recurrent and 30 (49%) metastatic 
disease. For 25 (42%) of the patients, palliative care was the 
primary treatment without any previous local or systemic 
disease-specific treatments.
Palliative period
Median survival after the primary diagnosis was 11 months 
(range 3 weeks–11.9 years). After referral to the Palliative 
Center, the median survival was 3 months (range 0–16) 
(Fig. 1). Thirty-four (56%) of the patients were referred to 
the Palliative Center by the multi-disciplinary Head and 
Neck tumour board, 12 (20%) by medical oncologists and 
six (10%) by radiation oncologists. The remaining patients 
were referred by other specialist units.
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Palliative treatment
Palliative treatments are described in Table 2.
Radiotherapy and surgery
None of the patients received palliative surgery during the 
follow-up period. Twenty-seven (45%) patients had PEG 
tube and 17 (28%) had tracheostomy.
A total of 33 (55%) patients received palliative radio-
therapy. Twenty-four (73%) of these patients received RT 
Table 1  Patient characteristics (n = 60)




Place of living during the palliative phase
 Home 51 (85%)
 Sheltered home 5 (8%)





 Missing data 1 (2%)
Major comorbidities 47 (78%)
Tumour site
 Oropharynx 20 (33%)
 Oral cavity 23 (38%)
 Salivary gland 3 (5%)
 Nasopharynx 2 (3%)
 Hypopharynx 4 (7%)
 Paranasal sinuses 2 (3%)
 Larynx 6 (10%)
Histology
 Squamous cell carcinoma 51 (85%)
 Adenoid cystic carcinoma 4 (6%)
 Melanoma 1 (2%)
 Neuroendocrine carcinoma 1 (2%)












 Surgery and (chemo)radiotherapy 21 (34%)
 Definitive (chemo)radiotherapy 10 (17%)
 Palliative treatment 26 (43%)
Treatment for local recurrence
 Surgery 6 (38%)
 Chemotherapy 2 (12%)
Treatment for metastatic disease
 Chemotherapy 11 (38%)
 Palliative treatment 19 (62%)
Fig. 1  Overall survival from the beginning of palliative treatment 
decision
Table 2  Palliative treatment (n = 60)
Treatment N (%)
Palliative RT 33 (55%)
Psychosocial support 4 (7%)
Nutrition counselling 4 (7%)
Physiotherapy 1 (2%)
Medication for symptom control
 Opioids at any phase of palliative treatment 59 (98%)






PEG tube 27 (45%)
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to the primary area (primary tumour, local recurrence 
or locoregional lymph node metastases). Of them, six 
had received prior RT as a part of the primary treatment 
with a curative intent. Fourteen (42%) of the 33 patients 
received palliative RT to distant metastatic sites, such 
as bone, lungs or thoracic lymph nodes, central nervous 
system, and subcutaneous or soft tissue metastases.
In the treatment of primary area, conventionally frac-
tionated RT with 30 in 3 Gy daily fractions was used 
ten times, 20 in 4 Gy daily fractions six times and 15 in 
3 Gy daily fractions twice. Three patients received one 
course of the “quad shot” [17] accelerated palliative RT 
with 3.5 Gy twice a day for 2 days up to a total dose of 
14 Gy. Ten single-fraction courses with either 8 or 6 Gy 
were given. In addition, despite the palliative intent, two 
patients received radical RT (one with 66 Gy and one 
70 Gy with concomitant weekly cisplatin, both with 2 Gy 
daily fractions) to the primary tumour area in an attempt 
to achieve better local control. The distant lesions were 
treated with 30 in 3 Gy fractions five times, 20 in 4 Gy 
fractions eight times, 15 in 3 Gy fractions twice, and with 
a single fraction three times. The mean number of pallia-
tive RT courses per patient was 1.4 (range 1–3). Eleven 
patients received two or more courses of palliative RT to 
the same site; seven of the re-irradiations were given to 
the primary tumour area.
Medical treatment
The medical treatments are listed in Table 3. Opioid use 
increased during the palliative phase: at the entry to the 
Palliative Center 30% of the patients were using long-
acting strong opioids and 32% were using weak opioids. 
At the last visit to the Palliative Center the corresponding 
rates were 70 and 8%, respectively. Palliative sedation 
was performed for one patient.
Complications
Infection was the most common severe complication during 
the palliative period (24 patients, 40%) followed by bleeding 
in 11 (18%), delirium in seven (12%), and airway obstruc-
tions in five (8%) patients. In addition, there were 12 (20%) 
cases of other complications including pulmonary embolism 
and spinal cord compression. Four patients had a massive 
bleeding from airways and one patient died due to it. One 
patient received an emergency tracheostomy.
Palliative care pathway
The median number of visits per patient to the Palliative 
Center was three (range 0–11). In addition, there were a 
median of three contacts per patient to the Palliative Center 
by phone (range 0–21).
The total number of visits to emergency units and hos-
pitalisations with the most common reasons are presented 
in Table 4.
Thirty-four (71%) patients received specialised palliative 
home care. Twenty-two (65%) of the 34 patients with and 15 
(58%) of the 26 patients without specialised home care made 
at least one visit to an emergency department (ED). The total 
number of the ED visits for these two groups was 35 and 40, 
respectively, and the mean number of visits per patient was 1 
and 1.5, respectively. The median number of hospitalisations 
at a university hospital for these two groups was 0.4 (range 
0–3) and 0.6 (range 0–4), respectively.
Place of death
Fifty-nine (98%) out of the 60 patients died during the fol-
low-up period. Fifteen patients (25%) died at home, nine 
patients (15%) died in a hospice, 14 (23%) at a specialised 
end-of-life care ward in a community hospital, 16 (27%) in a 
general primary care hospital ward, three (5%) at the univer-
sity hospital and three (5%) in a nursing home. Twelve (35%) 
out of the 34 patients who were supported by a specialised 
Table 3  Medical treatments Entry to the Palliative Centre Last visit to the Palliative Centre
n Mean dose Range n Mean dose Range
Strong opioids 18 42
 Oxycodone 9 54 mg/day 10–280 mg/day 16 90 mg/day 10–360 mg/day
 Fentanyl (transdermal) 9 72 μ/h 12–300 μ/h 22 68 μ/h 12–300 μ/h
 Morphine 0 4 49 mg/day 4–180 mg/day
Weak opioids 19 5
 Codeine 11 38 mg/day 30–120 mg/day 4 30 mg/day 30 mg/day
 Tramadol 7 150 mg/day 50–500 mg/day 0
 Buprenorphine (transdermal) 1 20 μ/h 20 μ/h 1 5 μ/h 5 μ/h
Short-acting opioids 18 51
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home care team, and three (12%) out of the 26 patients with-
out specialised home care died at home. There was no differ-
ence in the number of deaths at home between single-living 
and cohabitant patients.
Discussion
End-stage HNCs are characterised by heavy symptom bur-
den and short life expectancy. The symptoms related to 
locoregional tumour growth impact essential human func-
tions such as breathing, speaking, eating and swallowing. 
Facial mutilation as a result of tumour growth, local treat-
ment or both can cause major functional disability and 
have a negative impact on the integrity of body image [18]. 
Difficult physical symptoms and disfigurement cause enor-
mous psychological distress not only to patients but also 
to their families and caregivers [19]. This emphasises the 
importance of a specialised, well-organised palliative-care 
pathway.
Majority of HNC patients are diagnosed at an advanced 
stage when treatment options are limited and thus, their 
prognosis in general remains poor. In the present study, 
three quarters (77%) of patients had a locally advanced or 
metastatic disease. More than every third patient (42%) was 
referred to the Palliative Center at first presentation of the 
disease; this represents 9% of the newly diagnosed patients 
during that year in this university hospital region [1]. This 
proportion is comparable to the previous nationwide studies 
performed in Finland [2–5].
Overall survival in the present cohort was relatively short 
with a median of 11 months after primary diagnosis and 
only 3 months after the decision of withholding cancer-spe-
cific treatments. Previous retrospective studies [6, 7] have 
reported similarly short survival rates, with certain factors, 
such as disease stage, primary tumour location, palliative 
interventions, patient performance status, and comorbidity, 
having an impact on the prognosis. In their study of 808 
HNC patients without cancer specific treatments, Kowal-
ski et al. [6] reported a 3.8 months median overall survival, 
whereas Ledeboer et al. [7] reported that the median length 
of the palliative period was 5.3 months.
Over half the patients received palliative RT, and one-
third of them went through at least two courses of RT during 
follow-up. Palliative RT was given in most cases to the head 
and neck area; either due to locoregional recurrence after 
curative-intended primary treatment, or symptomatic locore-
gional tumour growth in a primarily incurable disease. The 
most common RT dose to the primary area was 30 with 3 Gy 
daily fractions. In addition to locoregional radiotherapy, a 
quarter of the patients received palliative radiotherapy to 
various distant lesions, most of which were uncomplicated 
bone metastases or metastases in the thoracic area. These 
were typically treated with single fractions or short fraction-
ated courses.
Although there is evidence that locoregional palliative 
treatments are beneficial for patients with non-curable 
locally advanced HNC [20], there is still no clear consensus 
on the optimal scheduling of palliative RT for these patients. 
Short hypofractionated courses of palliative RT are sup-
ported by several prospective [17, 21, 22] and retrospective 
[23–26] studies demonstrating both good tolerability and 
symptom control in this population with a very limited life 
expectancy. The high number of palliative locoregional re-
irradiations in our patient cohort emphasises the need for 
further investigations to determine the optimal palliative RT 
protocol for these patients.
There were a limited number of severe local complica-
tions among this highly symptomatic patient group, sug-
gesting that elective procedures to avoid major compli-
cations were successfully used. Likewise, locoregional 
Table 4  Use of various resources during the palliative period (n = 60)












 Coping problem 8 (10%)
 Bleeding 5 (6%)
 Other 27 (35%)
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complications were rarely the reason for ED visits or hos-
pitalisations. Percutaneous nutrition and prophylactic tra-
cheostomy were widely used among our patients, and only 
one patient needed an emergency tracheostomy. The use of 
strong opioids was common, and the number of opioid users, 
as well as the opioid doses, increased significantly during 
the follow-up.
However, although most patients had a round-the-clock 
access to specialised palliative care services, a relatively 
large proportion of the patients did visit an ED (66%) or 
got hospitalised in a university hospital (35%) during the 
last months of their lives. The leading causes of ED visits 
and hospitalisations were infections, pain, dyspnoea, and 
coping difficulties. For comparison, in a small retrospective 
study on 32 patients with HNC [8], bleeding was the most 
common reason for visiting an emergency unit, followed 
by pain, respiratory symptoms and swallowing problems. 
Some of the emergency visits and hospitalisations in our 
patient cohort would likely have been avoidable. This further 
emphasises the need for more intense follow-up of these 
patients.
According to a European study [27], 60% of people 
would prefer dying at home. A recent Cochrane review [28] 
reported that home-based end-of-life care services increase 
the likelihood of home deaths. In accordance with the 
Cochrane review, also in our cohort an access to specialised 
palliative home care seemed to increase the home-death rates 
(35% of the patients with specialised home care vs. 11% 
without it), but still, even with the support of specialised pal-
liative home care, only one-third of the deaths in our cohort 
did occur at home. These low home-death rates could partly 
be explained by the significant symptom burden, high rate 
of infections and the fact that half the patients were living 
alone, even though no difference in the rate of home deaths 
was found between the single-living and cohabitant patients. 
Further, the patients with a specialised palliative home care 
have a direct access to community hospital palliative wards 
whenever needed. Since some of the difficult symptoms may 
be easier to manage at a hospital ward, this could have fur-
ther reduced the home-death rates in this cohort.
There were some limitations in this study that should 
be pointed out. First, this was a small retrospective study, 
which limits further statistical analysis and makes this report 
a descriptive one. Second, the symptoms and their develop-
ment were not systematically reported in the patient records. 
Strength of this study is its population-based nature as all 
palliative-phase HNC patients in this university hospital 
region during one year were included. This area represents 
almost one-third of the Finnish population and there are no 
reasons to expect that the present series would differ from 
those in other regions in Finland.
In conclusion, a systematic collaboration with a Palliative 
Care Unit seems to assure sufficient end-of-life care to HNC 
patients with non-curable disease. Specialised palliative care 
pathway, particularly home care, increases the possibility for 
end-of-life care at home. Due to heavy symptom burden and 
short life expectancy in this patient population it is obvious 
that intense palliative care pathway from Cancer Center to 
home care is needed to ensure good quality of palliative care 
and a dignified death.
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